Corcept Therapeutics Inc. discovers, develops and sells drugs for severe metabolic, oncologic, and neuropsychiatric illnesses in the US. The company offers Korlym (mifepristone) for oral administration once a day for treating hyperglycemia secondary to hypercortisolism. Currently, the company is developing relacorilant and nab-paclitaxel to treat patients with advanced ovarian tumors, metastatic castration-resistant prostate cancer, and antipsychotic-induced weight gain, among other conditions.